Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Lymphoma 2Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

Carboplatin 47Etoposide 46durvalumab 28atezolizumab 27Cisplatin 21Topotecan 19pembrolizumab 15PM 01183 15Nivolumab 12Specimen Handling 11Drug Therapy 10anlotinib 9Radiotherapy 9Paclitaxel 9Temozolomide 8Magnetic Resonance Spectroscopy 8AMG 757 8Radiosurgery 7Platinum 7Irinotecan 7toripalimab 6olaparib 6Biopsy 6Ipilimumab 5Injections 5Docetaxel 5Bevacizumab 5trilaciclib 4tremelimumab 4tislelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Caves × 1 year × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡